ProterixBio Announces Commercial Availability COVID-19 Serology Test from Finger Stick

ProterixBio has announced commercial availability of a quantitative COVID-19 serology assay that has been validated for dried blood spots (DBS) from a finger stick. This is an update to the previously released SARS-CoV-2 (RBD) IgG Antibody test and is being offered as a testing service through ProterixBio's high-complexity CLIA testing laboratory.

ProterixBio has one of the only COVID-19 serology tests that provides a quantitative measurement of antibody levels associated with neutralizing activity and that has been validated with dried blood spots. There is growing interest in quantitative serology testing as follow up to COVID-19 vaccinations. The SARS-COV-2 (RBD) IgG Antibody test detects antibodies that bind to the Receptor Binding Domain (RBD) of the spike protein of the SARS-CoV-2 virus. The assay output is numerical value related to the levels of antibodies present and has been associated with neutralization titer. This allows the results to be interpreted on a standardized basis.

"Measuring and tracking levels of antibodies associated with neutralizing activity may help an individual together with their physician make better health decisions," said Michael Miller, Ph.D., President and Chief Executive Officer of ProterixBio. "The ability to perform this test on finger stick samples increases test accessibility by allowing easier, more convenient specimen collection by health care providers."